Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

JUN_02

Source date not recordedAnalyse record ↗

Preclinical siRNA program intended to modify gene networks relevant to obesity, with human safety studies planned for early 2027.

Modality
dual-targeted siRNA
Availability (US)
Preclinical; Phase 1 safety studies planned for early 2027
Hallmark targeted
deregulated nutrient sensing, transcriptional dysregulation
Kind
investigational drug